Thermo Fisher Scientific is acquiring Clario for roughly $8.9 billion, a major move to boost its clinical research services.

In recent days, Thermo Fisher Scientific has moved closer to its upcoming January 29, 2026 fourth-quarter and full-year 2025 earnings release, with investors closely tracking management’s pending ...

Clario, a clinical trial tech firm, has outlined three areas where artificial intelligence can improve patient experiences in the burgeoning landscape of decentralized clinical trials. In a study ...

Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies - ...

Endpoint solutions company Clario Inc. has published a roadmap on how artificial intelligence (AI) can be used to improve the experience of patients participating in decentralized clinical trials ...

Clinical trial tech firm Clario has joined forces with CellCarta to improve the way tissue and other samples are handled during trials. The collaboration will also encompass the digitization of the ...